Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kushner

Showing results (141-150 of 245) with videos related to

Pageof 25
Sort By:
JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Myeloablative combination chemotherapy without total body irradiation for neuroblastomaB H Kushner, R J O'Reilly, L R Mandell, et al.
Journal of the American College of Cardiology|May 10, 2001
Specificity of Doppler echocardiography for the assessment of changes in valvular regurgitation: comparison of side-by-side versus serial interpretationN J Weissman, J A Panza, J F Tighe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgeryB H Kushner, S Wolden, M P LaQuaglia, et al.
The Journal of Clinical Endocrinology and Metabolism|January 10, 2003
Androgen-responsive aspects of cognition in girls with Turner syndromeJ L Ross, D Roeltgen, G A Stefanatos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorNai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Hematology & Oncology|November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trialBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation TherapyThomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pageof 25

Showing results (141-150 of 245) with videos related to

Sort By:
Pageof 25
JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Myeloablative combination chemotherapy without total body irradiation for neuroblastomaB H Kushner, R J O'Reilly, L R Mandell, et al.
Journal of the American College of Cardiology|May 10, 2001
Specificity of Doppler echocardiography for the assessment of changes in valvular regurgitation: comparison of side-by-side versus serial interpretationN J Weissman, J A Panza, J F Tighe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgeryB H Kushner, S Wolden, M P LaQuaglia, et al.
The Journal of Clinical Endocrinology and Metabolism|January 10, 2003
Androgen-responsive aspects of cognition in girls with Turner syndromeJ L Ross, D Roeltgen, G A Stefanatos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorNai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Hematology & Oncology|November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trialBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation TherapyThomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pageof 25